# Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib

> **NCT07230314** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jinling Hospital, China** · enrollment: 34 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Donafina
- **DRUG:** PD-1/PD-L1 inhibitor

## Key facts

- **NCT ID:** NCT07230314
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07230314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07230314, "Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07230314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*